![]() |
市場調査レポート
商品コード
1778881
次世代シーケンスキット市場- 世界の産業規模、シェア、動向、機会、予測、ワークフロー別、シーケンスタイプ別、用途別、エンドユーザー別、地域別、競合別、2020~2030年Next Generation Sequencing Kits Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Workflow, By Sequencing Type, By Application, By End User By Region and Competition, 2020-2030F |
||||||
カスタマイズ可能
|
次世代シーケンスキット市場- 世界の産業規模、シェア、動向、機会、予測、ワークフロー別、シーケンスタイプ別、用途別、エンドユーザー別、地域別、競合別、2020~2030年 |
出版日: 2025年07月29日
発行: TechSci Research
ページ情報: 英文 188 Pages
納期: 2~3営業日
|
次世代シーケンスキットの世界市場は2024年に82億4,000万米ドルと評価され、予測期間中のCAGRは8.34%で2030年には132億2,000万米ドルに達すると予測されています。
次世代シーケンス(NGS)キットの世界市場は、臨床診断、学術研究、医薬品開発においてゲノム技術の利用が広まるにつれて急成長を続けています。NGSキットは、複雑なシーケンスワークフローを合理化し、DNAとRNAの高性能分析を卓越した速度と精度で可能にする不可欠なコンポーネントです。これらのキットは、がんゲノミクス、希少遺伝性疾患スクリーニング、非侵襲的出生前検査(NIPT)、病原体検出などの用途で特に不可欠です。
市場概要 | |
---|---|
予測期間 | 2026~2030年 |
市場規模:2024年 | 82億4,000万米ドル |
市場規模:2030年 | 132億2,000万米ドル |
CAGR:2025~2030年 | 8.34% |
急成長セグメント | シーケンス試薬キット |
最大市場 | 北米 |
市場成長の主要促進要因は、個別化医療に対する需要の高まりであり、NGSによって患者固有の遺伝子変異を同定し、オーダーメイドの治療計画を導くことが可能になります。この個別化医療へのシフトは、特に腫瘍学において顕著であり、NGSは腫瘍プロファイリングや治療反応のモニタリングにますます使用されるようになっています。例えば、2023年11月、Yourgene HealthとPacBioは、ロングリードシーケンスワークフローを強化するための協業を発表しました。PacBioは、長いDNA断片の効率的なサイズ選択を行うYourgeneのLightBench装置を承認しました。このパートナーシップは、シーケンスプロセスを合理化し、ゲノム分析の精度を向上させ、研究や臨床診断における先進的アプリケーションをサポートすることを目的としています。シーケンスのコストは近年大幅に低下しており、こうした技術は世界中の中小規模のラボやクリニックにとってより身近なものとなっています。
遺伝子疾患とがんの有病率の増加
初期設定と運用コストの高さ
シーケンス技術の進歩
Global Next Generation Sequencing Kits Market was valued at USD 8.24 billion in 2024 and is expected to reach USD 13.22 billion by 2030 with a CAGR of 8.34% during the forecast period. The Global Next Generation Sequencing (NGS) Kits Market continues to grow rapidly as the use of genomic technologies becomes more widespread across clinical diagnostics, academic research, and pharmaceutical development. NGS kits are essential components that streamline complex sequencing workflows, enabling high-throughput analysis of DNA and RNA with exceptional speed and accuracy. These kits are particularly vital in applications such as cancer genomics, rare genetic disorder screening, non-invasive prenatal testing (NIPT), and pathogen detection.
Market Overview | |
---|---|
Forecast Period | 2026-2030 |
Market Size 2024 | USD 8.24 Billion |
Market Size 2030 | USD 13.22 Billion |
CAGR 2025-2030 | 8.34% |
Fastest Growing Segment | Sequencing Reagents Kits |
Largest Market | North America |
A key driver of market growth is the rising demand for personalized medicine, where NGS enables the identification of patient-specific genetic mutations to guide tailored treatment plans. This shift toward individualized care is particularly evident in oncology, where NGS is increasingly used for tumor profiling and monitoring treatment response. For instace, in November 2023, Yourgene Health and PacBio announced a collaboration to enhance long-read sequencing workflows. PacBio approved Yourgene's LightBench instrument for efficient size selection of long DNA fragments. This partnership aims to streamline sequencing processes and improve accuracy in genomic analysis, supporting advanced applications in research and clinical diagnostics. The cost of sequencing has dropped significantly in recent years, making these technologies more accessible to small and mid-sized laboratories and clinics globally.
Key Market Drivers
Increasing Prevalence of Genetic Disorders and Cancer
The increasing prevalence of genetic disorders and cancer is a significant driver propelling the growth of the Global Next Generation Sequencing (NGS) Kits Market. Genetic disorders, including conditions such as cystic fibrosis, sickle cell anemia, and Duchenne muscular dystrophy, are affecting a growing portion of the global population. At the same time, cancer remains one of the leading causes of death worldwide, with an estimated 20 million new cancer cases diagnosed globally in 2022, according to the World Health Organization. Also, According to WHO 2025, anemia is a major global health concern, especially among young children, pregnant women, and menstruating girls and women. It disproportionately affects rural, low-income, and uneducated populations in low- and lower-middle-income countries. In 2019, anemia caused 50 million healthy life years lost, mainly due to iron deficiency, thalassaemia, sickle cell trait, and malaria. Early detection and accurate diagnosis are critical in managing these conditions, and NGS technologies are revolutionizing how clinicians identify genetic mutations and oncogenic alterations. NGS kits enable the rapid, comprehensive analysis of entire genomes or targeted gene panels, allowing researchers and healthcare professionals to detect pathogenic variants with high precision. In oncology, NGS is used extensively to perform tumor profiling, assess minimal residual disease, and guide treatment selection based on the genetic characteristics of individual tumors. This level of insight is not possible with traditional diagnostic methods. As a result, hospitals and diagnostic laboratories are increasingly incorporating NGS into routine testing protocols.
The rise in inherited genetic disorders has underscored the need for carrier screening, newborn screening, and prenatal testing-all areas where NGS kits play a central role. The growing use of non-invasive prenatal testing (NIPT) and whole-exome or whole-genome sequencing in pediatrics further amplifies demand. The public and private investments in genomics research aimed at understanding genetic diseases have boosted the deployment of NGS kits in research settings. With the global burden of cancer and genetic disorders on the rise, the demand for accurate, efficient, and cost-effective diagnostic tools will continue to accelerate, making NGS kits indispensable in both clinical and research environments.
Key Market Challenges
High Initial Setup and Operational Costs
High initial setup and operational costs represent one of the most significant challenges in the Global Next Generation Sequencing (NGS) Kits Market, particularly for smaller laboratories, research institutions, and healthcare facilities in low- and middle-income countries. While the cost of sequencing per genome has decreased over the years, the overall investment required to establish and maintain an NGS infrastructure remains substantial. This includes the purchase of high-throughput sequencing platforms, automated sample preparation systems, data analysis tools, and the NGS kits themselves, which are often costly due to their complexity and specificity. Beyond hardware and consumables, operational costs include regular maintenance, calibration, and the need for skilled personnel to manage sequencing workflows and interpret complex genomic data. In addition, storage and management of large datasets generated by NGS require robust IT infrastructure, including secure servers and advanced bioinformatics software-further adding to the total cost burden. These financial barriers can delay or even prevent the adoption of NGS technologies in many clinical and research settings, despite growing demand for advanced genomic testing in oncology, rare diseases, and infectious disease surveillance. The high cost structure also limits the ability of healthcare systems to offer NGS-based testing at scale, particularly in public health programs.
To address these challenges, market players are exploring cost-reduction strategies such as miniaturized sequencing platforms, simplified library preparation kits, and cloud-based bioinformatics solutions. The broader adoption depends on public-private partnerships, government subsidies, and expanded reimbursement frameworks that help offset upfront costs and make NGS technologies more accessible globally.
Key Market Trends
Advancements in Sequencing Technologies
Advancements in sequencing technologies are significantly shaping the future of the Global Next Generation Sequencing (NGS) Kits Market. Over the past decade, NGS has seen rapid progress in both its capabilities and accessibility, leading to a surge in applications across clinical diagnostics, research, and personalized medicine. These innovations are not only enhancing the accuracy and throughput of NGS but also reducing the cost and time required for sequencing, making it more accessible to a broader range of laboratories and healthcare providers. One of the most notable advancements is the development of single-molecule sequencing technologies. Companies like Oxford Nanopore Technologies have introduced platforms that sequence DNA directly without the need for amplification, allowing for longer reads and improved resolution of complex genomic regions. This is particularly valuable in areas like structural variation detection and de novo genome assembly, which were challenging with traditional sequencing technologies.
Another significant advancement is short-read sequencing improvements, especially by market leaders like Illumina, which have optimized their platforms for better accuracy, speed, and cost-effectiveness. These advancements are critical for large-scale projects and clinical applications, where speed and precision are essential. The introduction of long-read sequencing technologies is enabling more detailed and comprehensive genome analyses, allowing for the detection of rare mutations and previously undetectable genomic variations. The emergence of portable and miniaturized sequencing devices is also transforming the NGS market. These compact devices, such as the MinION from Oxford Nanopore, offer real-time sequencing capabilities, making genomic analysis possible in resource-limited settings and field-based applications. The integration of AI and machine learning into sequencing workflows is enhancing data analysis. These technologies are improving the ability to identify meaningful genetic variants and speed up the process of data interpretation, which is a critical factor in the clinical application of NGS technologies. These advancements are not only enhancing the capabilities of NGS kits but are also driving their broader adoption across a variety of industries, from healthcare to agriculture and environmental science, making NGS an indispensable tool for the future.
In this report, the Global Next Generation Sequencing Kits Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Therapeutic Plasma Exchange Market.
Global Next Generation Sequencing Kits Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report: